Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Phase 2
30
about 3 years
15+
2 sites in CA, NY
What this study is about
This trial is testing if rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) is beneficial for people with high-risk B-cell PTLD during their second phase of treatment. It's also evaluating the use of circulating tumor DNA (ctDNA), a blood test that may help guide treatment decisions in lymphoma patients, to see if it can be used to personalize treatment and reduce side effects without losing effectiveness.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Cyclophosphamide
- 2.Take Doxorubicin
- 3.Take Etoposide
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), etoposide, prednisone, rituximab (Monoclonal antibody; targets CD20 on B-cells to destroy them), vincristine
infusion, injection, intravenous, oral
Primary: Number of participants with Complete Response (CR) rate of 60% or higher
Secondary: Duration of Overall Response (OR), Event Free Survival rate, Progression-Free Survival (PFS) rate
Oncology